| thalidomide / Generic mfg. |
ChiCTR-OCC-10001120: Study of effect of health education on treatment compliance and quality of life in arthritis |
|
|
| Completed | 4 | 232 | | health education, Health Manual ;Questionnaire survey | Medical College of Yangzhou University; Technological Department of Jiangsu Province, Technological Department of Jiangsu | arthritis | | | | |
2012-001813-17: A study of the reaction of the vessels and cells of patients with myeloma getting chemotherapy. |
|
|
| Ongoing | 4 | 110 | Europe | Revlimid, Cyclophosphamide, Bortezomib, Thalidomide, Dexamethasone, PL 00032/0335, EU/1/04/274/001, EU/1/08/443/001, PL0065/5045R, Revlimid, Cyclophosphamide, VELCADE, Thalidomide, Dexamethasone, Revlimid, Cyclophosphamide, VELCADE, Thalidomide, Dexamethasone | Hull and East Yorkshire Hospitals NHS Trust | Chemotherapy related thrombosis in patients treated for multiple myeloma. | | | | |
ChiCTR-OPC-16008655: Efficacy and safety of thalidomide for patients with Crohn's Disease: a prospective multicenter observational study from China |
|
|
| Recruiting | 4 | 270 | | Thalidomide 75-100mg qd ;Thalidomide 150-200mg qd ;Thalidomide 75-100mg qd+MTX 20-25mg /W | Peking Union Medical College Hospital; Peking Union Medical College Hospital, None | Crohn‘s Disease | | | | |
ChiCTR-TRC-14004693: Clinical Trial of Therapy with Combination of Thalidomide and Interferon in Refractory or Relapsed Indolent Non-Hodgkin’s Lymphoma |
|
|
| Recruiting | 4 | 200 | | Thalidomide and Interferon ;Thalidomide and Interferon | The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital; Level of the institution：, self-financed | Indolent Non-Hodgkin’s Lymphoma | | | | |
ChiCTR-IPR-16008422: Randomized controlled study of the combination regimen of bortezomib + cyclophosphamide + dexamethasone (BCD) and bortezomib +thalidomide + dexamethasone (BTD) for the initial treatment of primary systemic amyloidosis (AL) |
|
|
| Recruiting | 4 | 120 | | the combination regimen of bortezomib + cyclophosphamide + dexamethasone (BCD) ;the combination regimen of bortezomib +thalidomide + dexamethasone (BTD) | People's Hospital, Beijing University; People's Hospital, Beijing University, self-paying | primary systemic amyloidosis (AL) | | | | |
ChiCTR-IPR-16009759: Optimization of low dosage thalidomide Treatment and prevention Schemes for minor aphthous ulcer |
|
|
| Not yet recruiting | 4 | 125 | | Dosage Gradient Thalidomide Administration ;No Thalidomide treatment ;No intervention | Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine; Shanghai Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine, Self-financing | Recurrent Aphthous Ulcer | | | | |
ChiCTR-IPR-17011696: A prospectie, randomized control, multicenter clinical study: the preventive and therapeutic effect of thalidomide to the radiation-induced oral mucous of nasopharyngeal carcinoma |
|
|
| Not yet recruiting | 4 | 160 | | thalidomide (75mg, qn) and mouthwash from Day 1 of radiation therapy to week 6-7 ;mouthwash from Day 1 of radiation therapy to week 6-7 | Sixth Affiliated Hospital of Guangxi Medical University; Sixth Affiliated Hospital of Guangxi Medical University, self-financing | radiation-induced oral mucositis | | | | |
ChiCTR-IPR-16008640: A single-center, prospective, randomized controlled trial of thalidomide plus CHOP-like regimen on newly diagnosed aggressive T-cell lymphoma |
|
|
| Recruiting | 4 | 50 | | thalidomide plus CHOP-like regimen ;CHOP-like chemotherapy | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, self-finacing | Aggressive T-cell lymphoma | | | | |
ChiCTR-IPR-17011608: The evaluation on the efficacy of thalidomide reducing the recurrence frequency of RAU |
|
|
| Not yet recruiting | 4 | 50 | | thalidomide ;prednisone | West China Hospital of Stomatology, Sichuan University; West China Hospital of Stomatology, Sichuan University, Self-financing | recurrent aphthous ulceration | | | | |
| Not yet recruiting | 4 | 40 | | thalidomide | Wuzhou GongRen Hospital of Guangxi Zhuang Autonomous Region; Wuzhou GongRen Hospital of Guangxi Zhuang Autonomous Region, Wuzhou GongRen Hospital of Guangxi Zhuang Autonomous Region | Thalassemia | | | | |
ChiCTR1800015163: A Prospective clinical study: the preventive and therapeutic effect of thalidomide to the radiation-induced oral mucous of nasopharyngeal carcinoma |
|
|
| Not yet recruiting | 4 | 200 | | Thalidomide 70mg/m^2 qn from Day -3 to the end of the radiation therapy (6-7weeks), Aspirin 100mg qn at the same time to prevention of thrombosis. Then the drug was observed until the end of radiotherapy for 2 weeks. ;Oral zinc gluconate tablet 70 mg (zinc 10 mg) bid from Day -3 to the end of the radiation therapy (6-7weeks). Then the drug was observed until the end of radiotherapy for 2 weeks. | Jianyang people's Hospital; Jianyang people's Hospital, self-financing | radiation-induced oral mucositis | | | | |
ChiCTR-OPC-17010963: Clinical study of thalidomide combined with temozolomide in the postoperative treatment of patients with glioblastoma: a single arm, open, multicenter phase II clinical trial |
|
|
| Not yet recruiting | 4 | 157 | | Thalidomide | Fujian Cancer Hospital; Fujian Provincail Hospital, None | Glioblastoma | | | | |
ChiCTR1800016845: Thalidomide in the treatment of bone metastases with moderate anemia: a prospective, randomized controlled clinical trial |
|
|
| Recruiting | 4 | 280 | | Thalidomide+zoledronic acid ;zoledronic acid | Affiliated Sixth People's Hospital, Shanghai Jiaotong University; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Self-financing | advanced malignant tumors | | | | |
ChiCTR1900025219: A prospective, open-label, multicenter clinical trail for Ruxolitinib combined with Prednisone, Thalidomide and Danazole in adult patients wiht myelofibrosis |
|
|
| Not yet recruiting | 4 | 80 | | Ruxolitinib combined with Prednisone, Thalidomide and Danazol | Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Institute of Hematology and Blood Diseases Hospital,Chinese Academy of Medical Sciences | myelofibrosis | | | | |
ChiCTR2000033205: Efficacy of thalidomide in the treatment of patients with non-transfusion dependent thalidomide anemia |
|
|
| Recruiting | 4 | 20 | | The first stage: thalidomide 25mg / day oral, treatment 3 months (12 weeks); the second stage: first stage: thalidomide reduction of 12.5mg / day oral, treatment 3 months (12 weeks ). | The People's Liberation Army Joint Logistics Support Unit 923th Hospital; The People's Liberation Army Joint Logistics Support Unit 923th Hospital, This study is a curative effect study, using self-control and collecting the data of the patient's re-examination results, without additional funds. | Thalassemia | | | | |
ChiCTR2000034998: A prospective study of thalidomide in the treatment of β-thalassemia in children |
|
|
| Not yet recruiting | 4 | 48 | | Oral thalidomide | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University-; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, National Natural Science Foundation of China, Guangdong Natural Science Committee Project | β-thalassemia | | | | |
ChiCTR-IPR-17012637: Prospective Randomized controlled study of the combination regimen of bortezomib + thalidomide + dexamethasone (VTD) and bortezomib + cyclophosphamide + dexamethasone (VCD) for the initial treatment of type AL amyloidosis |
|
|
| Not yet recruiting | 4 | 70 | | the combination regimen of bortezomib +thalidomide + dexamethasone (VTD) ;the combination regimen of bortezomib + cyclophosphamide + dexamethasone (VCD) | Guangdong General Hospital; Guangdong General Hospital, self-paying | type AL amyloidosis | | | | |
ChiCTR1900022510: A study for Efficacy and Safety of Metronomic Administration of Detoxification Chinese Herbs combined with Thalidomide in the Treatment of Elderly or Refractory Relapsed Lymphoma |
|
|
| Recruiting | 4 | 70 | | detoxification Chinese herbs +thalidomide ;traditional Chinese medicine simulator+thalidomide | Shanghai Municiple hospital of Traditional Chinese Medicine; Shanghai Municiple Hospital of Traditional Chinese Medicine, Self-paying | Relapsed or Refractory Non-Hodgkin's lymphoma | | | | |
ChiCTR2000038265: Single-arm, prospective, exploratory clinical study of Carrizumab combined with thalidomide, Pemetrexed and carboplatin in the first-line treatment of advanced non-squamous cell non-small cell lung cancer |
|
|
| Recruiting | 4 | 20 | | Carrizumab+ thalidomide + Pemetrexed + carboplatin | Affiliated Hospital of Xuzhou Medical University; Affiliated Hospital of Xuzhou Medical University, Self-financing | Non-squamous cell lung cancer | | | | |
ChiCTR1800016856: A prospective, randomized, controlled clinical trial of thalidomide against small molecule VEGFR oral targeted drug grade III-IV adverse reactions |
|
|
| Recruiting | 4 | 440 | | Apatinib + thalidomide 50~150mg/d, po.QN ;Apatinib ;Anlotinib Hydrochloride + thalidomide 50~150mg/d, po.QN ;Anlotinib ;Apatinib + thalidomide 50~150mg/d, po.QN ;Apatinib ;Anlotinib Hydrochloride + thalidomide 50~150mg/d, po.QN ;Anlotinib | Affiliated Sixth People's Hospital, Shanghai Jiaotong University; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Self-raised | Patients with advanced gastric cancer, lung cancer, and osteosarcoma taking apatinib or antatinib | | | | |
ChiCTR2100045323: Randomized controlled study of the combination regimen of Thalidomide and olanzapine + 5-HT receptor antogonist + hormonotherapy for the prevention of delayed nausea and vomiting induced by highly emetogenic chemotherapy |
|
|
| Recruiting | 4 | 140 | | Thalidomide 100mg qd1-5 ;Olanzapine 10mg d1-4 | Hainan General Hospital; Hainan general hospital, None | Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy | | | | |
ChiCTR2000028918: A randomized, double-blind controlled study of glucocorticoids combination with thalidomide in the treatment of IgG4-related diseases |
|
|
| Recruiting | 4 | 102 | | prednison combined with placebo ;prednison combined with thalidomide | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Tongji Hospital Clinical Research Flagship Program | IgG4 related disease | | | | |
NCT05525234: A Study of Thalidomide in the Treatment of Refractory Uremic Pruritus |
|
|
| Not yet recruiting | 4 | 40 | NA | Thalidomide, Placebo | RenJi Hospital | Haemodialysis, Uremic Pruritus, Thalidomide | 12/22 | 01/23 | | |
| Recruiting | 4 | 70 | RoW | Thalidomide, Bortezomib, Dexamethason, Cyclophosphamide | Guangdong Provincial People's Hospital | Immunoglobulin Light-Chain Amyloidosis | 01/23 | 06/23 | | |
NCT06299670: Efficacy of Combination of Hdroxyurea and Thalidomide Over Either Hydroxyurea or Thalidomide Alone in the Treatment of Transfusion Dependent Thalassemia in Children: A Quasi-Randomised Clinical Trial |
|
|
| Recruiting | 4 | 90 | RoW | Thalidomide, Hydroxy Urea, Combinations | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Transfusion-dependent Thalassemia | 06/24 | 12/24 | | |
ChiCTR2000035500: A prospective randomized controlled trial of thalidomide in the treatment of refractory tuberculous meningitis |
|
|
| Not yet recruiting | 4 | 40 | | Basic antituberculosis standard scheme drug + hormone + thalidomide ;Basic antituberculosis standard scheme drug + hormone | Shanghai Public Health Clinical Center; Shanghai Public Health Clinical Center, Shenkang three year action plan | Refractory tuberculous meningitis | | | | |
MA-NSCLC-II-039, NCT06276933: A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) |
|
|
| Not yet recruiting | 4 | 104 | NA | Camrelizumab + chemotherapy+Thalidomide, Camrelizumab + chemotherapy+placebo | Tongji University, Shanghai Pulmonary Hospital, Shanghai, China | Lung Cancer, Camrelizumab | 11/25 | 11/26 | | |
NCT06438679: 3T Therapy in the Treatment of MDA5-positive Dermatomyositis |
|
|
| Enrolling by invitation | 4 | 133 | RoW | Tofacitinib 5 MG, tacrolimus, thalidomide | Second Affiliated Hospital, School of Medicine, Zhejiang University | Dermatomyositis | 09/24 | 12/26 | | |
NCT05527444: The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients |
|
|
| Active, not recruiting | 4 | 100 | RoW | Secukinumab 150 mg/ml, Secukinumab, Adalimumab Ab, Adalimumab, NSAID, Thalidomide Pill | Qilu Hospital of Shandong University | Ankylosing Spondylitis | 12/24 | 12/24 | | |
| Active, not recruiting | 3/4 | 40 | | | Hospital das Clínicas, Sao Paulo University, Sao Paulo University | Recurrent aphthous stomatitis | | | | |
ACTRN12616001030460: A Multicentre Phase 3 Trial Comparing Elotuzumab-Cyclophosphamide-Thalidomide-Dexamethasone (E-CTD) with Cyclophosphamide-Thalidomide-Dexamethasone (CTD) for the Treatment of Relapsed and/or Refractory Multiple Myeloma (RRMM) |
|
|
| Recruiting | 3 | 300 | | | Australasian Leukaemia and Lymphoma Group (ALLG), Bristol-Myers Squibb | Multiple Myeloma | | | | |
ACTRN12607000382471: A multicentre randomised phase III study of low-dose thalidomide, prednisolone and zoledronic acid versus prednisolone and zoledronic acid for post-autologous stem cell transplant (ASCT) maintenance therapy in patients with multiple myeloma (MM6) |
|
|
| Completed | 3 | 250 | | | Australasian Leukaemia and Lymphoma Group, Amgen, Schering Plough, Pharmion | Multiple Myeloma | | | | |
NCT00098475: Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma |
|
|
| Active, not recruiting | 3 | 452 | US | Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Thalidomide, (+)-Thalidomide, (-)-Thalidomide, .alpha.-Phthalimidoglutarimide, 2, 6-Dioxo-3-phthalimidopiperidine, Alpha-Phthalimidoglutarimide, Contergan, Distaval, Kevadon, N-(2,6-Dioxo-3-piperidyl)phthalimide, N-Phthaloylglutamimide, N-Phthalylglutamic Acid Imide, Neurosedyn, Pantosediv, Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (+)-, Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (-)-, Sedalis, Sedoval K-17, Sedoval K17, Softenon, Synovir, Talimol, Thalomid | National Cancer Institute (NCI) | DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma | 11/08 | 10/24 | | |
ACTRN12609000141246: MATES: Maintenance Thalidomide in Mesothelioma Patients. A phase III trial of anti-angiogenic agent Thalidomide in patients with malignant pleural mesothelioma after first line chemotherapy. |
|
|
| Completed | 3 | 100 | | | University of Sydney, National Health and Medical Research Council | Unresectable malignant mesothelioma | | | | |
NCT00602641: Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma |
|
|
| Active, not recruiting | 3 | 306 | US, RoW | Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Quality-of-Life Assessment, Quality of Life Assessment, Thalidomide, (+)-Thalidomide, (-)-Thalidomide, .alpha.-Phthalimidoglutarimide, 2, 6-Dioxo-3-phthalimidopiperidine, Alpha-Phthalimidoglutarimide, Contergan, Distaval, Kevadon, N-(2,6-Dioxo-3-piperidyl)phthalimide, N-Phthaloylglutamimide, N-Phthalylglutamic Acid Imide, Neurosedyn, Pantosediv, Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (+)-, Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (-)-, Sedalis, Sedoval K-17, Sedoval K17, Softenon, Synovir, Talimol, Thalomid | National Cancer Institute (NCI) | Multiple Myeloma | 01/14 | 02/25 | | |
|
2005-000371-18: The use of Thalidomide as a treatment for the cachexia of incurable upper gastrointestinal adenocarcinomas:a randomised, double-blinded, placebo controlled trial. |
|
|
| Ongoing | 3 | 180 | Europe | Thalidomide, | Portsmouth Hospitals Trust | The cachexia associated with terminal gastrointestinal adenocarcinomas | | | | |
2004-000944-26: A randomized phase III study on the effect of Bortezomib combined with Adriamycin, Dexamethasone (AD) for induction treatment, followed by High Dose Melphalan and Bortezomib alone during maintenance in patients with multiple myeloma |
|
|
| Ongoing | 3 | 32 | Europe | dexamethasone, doxorubicin, Vincristine, filgrastim, thalidomide, melphalan, Velcade, Velcade | HOVON foundation | multiple myeloma | | | | |
2007-004007-34: Randomized phase III trial in elderly patients with previously untreated symptomatic Multiple Myeloma comparing MP-Thalidomide (MP-Thal) followed by thalidomide maintenance versus MP-Lenalidomide (MP-Len) followed by maintenance with lenalidomide Een gerandomiseerde fase III studie bij niet eerder voorbehandelde patienten met Multipel Myeloom, die niet in aanmerking komen voor hoge dosis chemotherapie, naar het effect van Melfalan Prednison en Thalidomide, gevolgd door onderhoudsbehandeling met Thalidomide versus Melfalan Prednison en Lenalidomide, gevolgd door onderhoudsbehandeling met Lenalidomide. |
|
|
| Ongoing | 3 | 500 | Europe | Revlimid, Thalidomide Celgene, Revlimid, Thalidomide Celgene | HOVON Foundation, Dutch Cancer Society, Celgene, | Multiple Myeloma | | | | |
ChiCTR-IPR-15006024: A Multicenter, Randomized, Double-Blind, Controlled Phase III Study of CPT or Placebo in Combination with Thalidomide and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 3 | 417 | | Circular Permuted TRAIL+Thalidomide+Dexamethasone ;Placebo+Thalidomide+Dexamethasone | CCMU Beijing Chaoyang Hospital; Beijing Sunbio Biotech Co., Ltd, self-financing | multiple myeloma | | | | |
ChiCTR-OIC-16008402: The efficientcy of thalidomide plus cyclophosphamide and dexamethasone following by thalidomide and prednisone maintaince therapy for the newly diagnosed Waldenstr?m macroglobulinemia - a Prospective Multicentre Phase III Trial from China |
|
|
| Recruiting | 3 | 44 | | chemotherapy | Institute of Hematology Blood Disease Hospital, Chinese Academy of Medical Sciences Peking Union Medical College; Institute of Hematology Blood Disease Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, State Science Technology Project in China | lymphoplasmacytic lymphoma / Waldenstrom macroglobulinemia | | | | |
| Recruiting | 3 | 226 | RoW | Thalidomide, Thalomid, Observation | Nanfang Hospital of Southern Medical University | Lymphoma, Large B-Cell, Diffuse | 12/19 | 12/23 | | |
ACTRN12616000772448: A Phase 3 trial of thalidomide-dexamethasone consolidation versus thalidomide-dexamethasone-Ixazomib consolidation for transplant eligible multiple myeloma patients undergoing a single autologous stem cell transplantation as part of front-line therapy |
|
|
| Active, not recruiting | 3 | 310 | | | Australasian Leukaemia and Lymphoma Group (ALLG), Takeda Pharmaceuticals U.S.A. Inc. | Multiple Myeloma | | | | |
| Active, not recruiting | 3 | 1085 | Europe | Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD), Arm A Part 1, Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab, Arm B Part 1, Daratumumab, Arm B Part 2 | Intergroupe Francophone du Myelome, HOVON - Dutch Haemato-Oncology Association, Janssen Research & Development, LLC | Multiple Myeloma | 08/20 | 06/23 | | |
|
|
|
|
| Active, not recruiting | 3 | 4420 | Europe | Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen, Revlimid (lenalidomide), Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen, Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen, Kyprolis (carfilzomib), Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen, Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen, Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen, Velcade (bortezomib), Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance, Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance, Zolinza (vorinostat), High dose melphalan therapy and autologous stem cell transplant (intensive pathway only) | University of Leeds, Celgene, Merck Sharp & Dohme LLC, Amgen | Multiple Myeloma | 12/21 | 12/22 | | |
|
|
NCT06146478: Deciphering Effects of Thalidomide on Red Blood Cells in Transfusion Dependents Beta Thalassemia Patients |
|
|
| Completed | 3 | 200 | RoW | Thalidomide, Bludomide | Blood Care Clinic, Khyber Medical University Peshawar | Transfusion-dependent Beta-Thalassemia | 07/23 | 10/23 | | |
NCT02085655: PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma |
|
|
| Recruiting | 3 | 264 | RoW | pegaspargase, Oncaspar, Gemcitabine, Gemzar, Oxaliplatin, Eloxatin, Methotrexate, Dexamethasone, Thalidomide | Huiqiang Huang, Sun Yat-sen University | Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type | 12/22 | 12/22 | | |
ChiCTR1900021382: A comparison between thalidomide, dexamethasone, bortezomib (VTD) and bortezomib, doxorubicin, dexamethasone (PAD) in eligible-transplant newly-diagnosed myeloma: a multicenter, randomized, open, phase 3 study |
|
|
| Not yet recruiting | 3 | 100 | | VTD regimen+SCT ;PAD regimen+SCT | Tianjin Medical University Cancer Institute and Hospital; Tianjin Medical University Cancer Institute and Hospital, Appropriation by Tianjin Medical University Cancer Institute and Hospital | Multiple myeloma | | | | |
NCT00572169: UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy |
|
|
| Active, not recruiting | 3 | 177 | US | Velcade, Bortezomib, PS-341, Thalidomide, Thalomid, Dexamethasone, Decadron, NSC-34521, Adriamycin, Doxorubicin, NSC-123127, Cisplatin, Cis-diamminedichloroplatinum [CDDP], Platinol, NSC-119875, Cyclophosphamide, Cytoxan, NSC-26271, Etoposide, VP-16), Vepesid®, Ethylidene-Lignan P., NSC-141540 | University of Arkansas | Multiple Myeloma | 08/25 | 08/25 | | |
|
NCT06031012: Glutamine Combined With Thalidomide in Preventing Radiation-induced Oral Mucositis |
|
|
| Not yet recruiting | 3 | 70 | RoW | glutamine combined with thalidomide, GT group, glutamine alone, G group | Air Force Military Medical University, China | Mucositis Oral | 08/24 | 10/24 | | |
TT4B, NCT00734877: UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma |
|
|
| Active, not recruiting | 3 | 382 | US | M-VTD-PACE, Melphalan, Velcade, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide, TT3-LITE Regimen (L-TT3), Velcade (bortezomib) | University of Arkansas, Millennium Pharmaceuticals, Inc. | Multiple Myeloma | 09/24 | 09/24 | | |
| Recruiting | 3 | 100 | RoW | Thalidomide, Nab paclitaxel, Gemcitabine | Fudan University | Pancreatic Cancer Stage IV, Chemotherapy-induced Nausea and Vomiting | 11/25 | 11/26 | | |
ACCoRd, NCT03562169: The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII |
|
|
| Recruiting | 3 | 406 | Europe | Ixazomib, thalidomide, & dexamethasone (ITD) re-induction, Conventional autologous stem cell transplant (ASCT-con), Augmented autologous stem cell transplant (ASCT-aug), ITD consolidation and ixazomib maintenance vs. No further therapy | University of Leeds, Cancer Research UK, Takeda | Multiple Myeloma | 03/26 | 03/27 | | |
2006-006395-37: A randomised, multi-centre feasibility trial in AL Amyloidosis, comparing CTD with SCT in patients with low risk of Treatment Related Mortality and CTD with Mel-Dex in patients in whom SCT would not be considered appropriate as first line therapy |
|
|
| Ongoing | 2/3 | 48 | Europe | Cyclophosphamide, Dexamethasone, Melphalan, Thalidomide, Lenogastrim, Lenogastrim | Joint UCLH and UCL Biomedical Research Unit | The medical condition to be investigated is systemic AL Amyloidosis, a disorder of protein folding in which normally soluble proteins are deposited as abnormal, insoluble fibrils that progressively disrupt tissue structure and impair function. | | | | |
NCT06153784: Thalidomide and Hydroxyurea Combination in β-Thalassemia Patients |
|
|
| Completed | 2/3 | 603 | RoW | Hydroxyurea and Thalidomide | Children's Hospital Karachi | Thalassemia, Beta | 07/23 | 07/23 | | |
NCT04453345: TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL |
|
|
| Recruiting | 2/3 | 42 | RoW | thalidomide + prednisone + methotrexate, TPM regimen | Institute of Hematology & Blood Diseases Hospital, The First Affiliated Hospital of Nanchang University, First Affiliated Hospital of Guangxi Medical University, Henan Cancer Hospital, First Hospital of Jilin University, Central South University, Tianjin First Central Hospital | T-LGL Leukemia, Clpd-Nk | 05/23 | 05/25 | | |
NCT03759093: CURATE.AI Optimized Modulation for Multiple Myeloma |
|
|
| Recruiting | 2/3 | 20 | RoW | Bortezomib, Velcade, Cyclophosphamide, Dexamethasone, CURATE.AI-Guided dosage modulation, Thalidomide, Lenalidomide, Revlimid | National University Hospital, Singapore, National University of Singapore | Multiple Myeloma | 09/25 | 09/25 | | |
ACTRN12606000372583: A study evaluating the role of docetaxel (Taxotere) in combination with thalidomide in men with hormone refractory prostate cancer |
|
|
| Active, not recruiting | 2 | 35 | | | Royal North Shore Hospital, Educational grant from Sanofi Aventis, Educational grant from Pharmion, Cancer Trials NSW | Prostate cancer | | | | |
ChiCTR-TRC-13003449: A multicenter, randomized, double-blind, placebo-controlled, Phase II clinical study of Thalidomide in the treatment of Ankylosing Spondylitis |
|
|
| Completed | 2 | 200 | | Thalidomide 25mg/qd.po.2weeks; 50mg/qd.po.2weeks;100mg/qd.po.2weeks; 150mg/qd, po., to the end ;Thalidomide 25mg/qd.po.2weeks; 50mg/qd.po.2weeks; 100mg/qd.po.to the end ;Placebo po. | The General Hospital of People's Liberation Army; Changzhou Pharmaceutical Factory, Self-financing | Ankylosing Spondylitis | | | | |
ChiCTR-TRC-08000081: A controlled randomized trial of transcatheter arterial chemoembolization combined thalidomide on hepatocellular carcinoma |
|
|
| Completed | 2 | 200 | | Patients take thalidomide 100 mg/d for 7 days after TACE and take thalidomide 200 mg/d in succession ;TACE alone | FuJian Provincial Tumour Hospital; Level of the institution：, Self-funded | Hepatocellular carcinoma | | | | |
| Completed | 2 | 43 | | CPT+Thal | CCMU Beijing Chaoyang Hostipital; Beijing Sunbio Biotech Co., Ltd., Beijing Sunbio Biotech Co., Ltd. | Relapsed or Refractory Multiple Myeloma | | | | |
ChiCTR-TNC-13003013: The effect of paclitaxel combined with thalidomide on refractory metastatic osteosarcoma:a phase II clinical trial. |
|
|
| Completed | 2 | 50 | | paclitaxel plus thalidomide | Department of oncology, Shanghai 6th Hospital; Shanghai Sixth People's Hospital, Sponsored by Cancer Foundation of China and Bristol-Myers Squibb company. | osteosarcoma | | | | |
2005-001503-19: CLINICAL AND BIOLOGICAL STUDY ON THE ADMINISTRATION OF THALIDOMIDE IN PATIENTS WITH PRIMARY CANCER OF THE LIVER |
|
|
| Ongoing | 2 | | Europe | thalidomide, | ISTITUTO EUROPEO DI ONCOLOGIA | PRIMARY CANCER OF THE LIVER | | | | |
2005-004624-38: A Phase II, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of Velcade® added to Thalidomide-Dexamethasone Standard Treatment in Subjects with Multiple Myeloma who are Refractory to or Have Relapsed after Primary Therapy for Multiple Myeloma |
|
|
| Ongoing | 2 | 12 | Europe | Velcade 3,5 mg, Velcade, Velcade | Janssen-Cilag EMEA Medical Affairs | multiple myeloma | | | | |
2006-005831-44: A new induction therapy (ThalDoDex) for multiple myeloma. A phase II study. |
|
|
| | 2 | 35 | Europe | Thalidomide, MYOCET*INFUS 2SET 50MG, SOLDESAM*OS GTT 10ML 0,2%, MYOCET*INFUS 2SET 50MG, SOLDESAM*OS GTT 10ML 0,2% | ISTITUTO EUROPEO DI ONCOLOGIA | Multiple Myeloma | | | | |
2007-007939-29: A PHASE II,MULTI-CENTER, OPEN LABEL STUDY OF ORAL LBH589 PLUS MELPHALAN, PREDNISONE AND THALIDOMIDE (LB-MPT)IN ADVANCED, REFRACTORY MULTIPLE MYELOMA PATIENTS. |
|
|
| Ongoing | 2 | 42 | Europe | Thalidomide, Thalidomide | FONDAZIONE NEOPLASIE SANGUE ONLUS | Patients with refractory or advanced Multiple Myeloma. | | | | |
2009-014922-40: Carfilzomib in combination with Thalidomide and Dexamethasone for remission induction and consolidation of Multiple Myeloma at first presentation |
|
|
| Ongoing | 2 | 50 | Europe | CARFILZOMIB, PR-171, | Erasmus MC, Onyx pharmaceuticals | Multiple myeloma at first presentation Multipel myeloom | | | | |
2010-021451-12: Bendamustine, thalidomide and dexamethasone in relapsed/refractory myeloma |
|
|
| Ongoing | 2 | 98 | Europe | Bendamustine, Thalidomide, Dexamethasone, Levact, Celgene Thalidomide, Dexamethasone, Levact, Celgene Thalidomide, Dexamethasone | University of Leeds | Relpsed or refractory multiple myeloma | | | | |
2013-003266-14: Ixazomib citrate-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib citrate or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; a randomized phase II trial Inductiebehandeling met ixazomib citraat, thalidomide en lage dosis dexamethason gevolgd door onderhoudsbehandeling met ixazomib citraat of placebo bij niet eerder behandelde patiënten met Multipel Myeloom, die niet in aanmerking komen voor autologe stamceltransplantatie. Een gerandomiseerde fase II studie. |
|
|
| Ongoing | 2 | 71 | Europe | Ixazomib citrate (4 mg), Ixazomib citrate (3mg), Ixazomib citrate (2.3 mg), | HOVON Foundation, Dutch Cancer Society, | Multiple Myeloma | | | | |
2014-002749-23: Ixazomib in combination to thalidomide - dexamethasone for patients with relapsed and/or refractory multiple myeloma |
|
|
| Ongoing | 2 | 45 | Europe | Thalidomide, Dexamethasone, ixazomib, Thalidomide, MLN9708, | AGMT gGmbH, Millennium Pharmaceuticals Inc. | refractory and/or relapsed multiple myeloma | | | | |
| Ongoing | 2 | 20 | Europe | thalidomide, Celecoxib, Fenofibrate, Etoposide, Cyclophosphamide, Avastin, DepoCyte, Avastin, DepoCyte | Masaryk University, Masaryk University | recurrent or progressive medulloblastoma recidivující/progredující meduloblastom | | | | |
ACTRN12615000934549: A multicentre single arm study of carfilzomib-thalidomide-dexamethasone (CarTD) for newly diagnosed transplant-eligible multiple myeloma (MM) patients refractory to initial bortezomib-based induction therapy |
|
|
| Active, not recruiting | 2 | 50 | | | Australiasian Leukaemia and Lymphoma Group, Onyx Pharmaceuticals Inc., a subsidiary of Amgen, Inc. | Multiple Myeloma | | | | |
ACTRN12616000894493: A prospective, multi-centre, single arm, phase 2 assessment of the efficacy and safety of the combination of ixazomib, thalidomide and dexamethasone (ITD) for relapsed and/or refractory multiple myeloma after 1 to 3 prior lines of therapy. |
|
|
| Completed | 2 | 45 | | | Professor Andrew Spencer, Takeda Oncology | Multiple Myeloma | | | | |
| Not yet recruiting | 2 | 120 | Europe | Thalidomide celgene, Velcade, Levact, J9041, Capsule, hard, Injection, Infusion, Thalidomide Celgene™, Velcade, Levact | Oxford University Hospitals NHS Trust, Janssen-Cilag, NAPP Pharmaceuticals | Myeloma and renal impairment, Cancer of bone marrow, kidney disfunction, Diseases [C] - Cancer [C04] | | | | |
ACTRN12615000818538: Single arm, multicentre study of Carfilzomib in combination with Thalidomide and Dexamethasone (CaTD) in patients with relapsed and/or refractory multiple myeloma (RRMM). |
|
|
| Completed | 2 | 100 | | | Australiasian Leukaemia and Lymphoma Group, Australasian Leukaemia and Lymphoma Group | Multiple Myeloma | | | | |
ChiCTR-OIC-17012859: Efficacy and Safety of Thalidomide Combined with rhTPO in the Treatment of Corticosteroid-resistant or Relapsed ITP: a Single Arm Clinical Study |
|
|
| Recruiting | 2 | 33 | | Thalidomide + rhTPO | Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University, The Clinical research project, Affiliated Hospital of Guangdong Medical University | Immune Thrombocytopenia | | | | |
ChiCTR-OIC-17012860: Efficacy and Safety of Thalidomide Combined with Cyclosporine in the Treatment of Corticosteroid-resistant or Relapsed ITP: a Single Arm Clinical Study |
|
|
| Recruiting | 2 | 33 | | Thalidomide + Cyclosporine | Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University, The Clinical research project, Affiliated Hospital of Guangdong Medical University | Immune Thrombocytopenia | | | | |
ChiCTR-IIR-17012850: A randomized controlled trial of Comparing the Efficacy and Safety of High-dose Dexamethasone Combining THD Versus High-dose Dexamethasone Combining Low-dose Prednisone in Newly Diagnosed ITP |
|
|
| Recruiting | 2 | 38 | | Dexamethasone + Thalidomide ;Dexamethasone + prednisone | Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University, The Clinical research project, Affiliated Hospital of Guangdong Medical University | Immune Thrombocytopenia | | | | |
ACTRN12615000188538: KIWI Study- Kyprolis based Induction in untreated Myeloma with Kyprolis post Transplant Consolidation |
|
|
| Active, not recruiting | 2 | 50 | | | North Shore Haematology Clinical Trial Unit, Amgen Inc | Multiple Myeloma | | | | |
ChiCTR1900022946: A phase II study for Tegafur, Gimeracil and Oteracil potassium with or without Thalidomide for heavily treated colorectal cancer patients |
|
|
| Not yet recruiting | 2 | 100 | | Tegafur combined with Thalidomide ;Tegafur | First Affilliated Hospital of Xi'an Jiaotong University; First Affilliated Hospital of Xi'an Jiaotong University, Funding from the first affiliated hospital of Xi'an Jiaotong University | colorectal cancer | | | | |
ChiCTR1800015212: A prospective, randomized controlled trial of Thalidomide plus Gefitinib vs Gefitinib for the first-line treatment of advanced lung adenocarcinoma patients with EGFR-sensitive mutation |
|
|
| Not yet recruiting | 2 | 60 | | Thalidomide+Gefitinib ;Gefitinib | Fujian Provincial Cancer Hospital; Fujian Provincial Cancer Hospital, No | advanced lung adenocarcinoma with EGFR-sensitive mutation | | | | |
NCT06239389: Comparison Of Efficacy And Safety Of Thalidomide Vs Hydroxyurea In Thalassemia Patients: A Single-Centre Pilot Study. |
|
|
| Completed | 2 | 24 | RoW | Thalidomide 100mg, thalido, Hydroxyurea, Hydrea | National Institute of Blood and Marrow Transplant (NIBMT), Pakistan | Beta-Thalassemia | 12/21 | 03/22 | | |
NCT06470464: Thalidomide Combined With Chemotherapy in the Treatment of Relapsed or Refractory Yolk Sac Tumor |
|
|
| Completed | 2 | 20 | RoW | Thalidomide combined with TGA chemotherapy (nab-paclitaxel + gemcitabine+ epirubicin) | Shandong First Medical University | Germ Cell Tumor, Yolk Sac Tumor | 06/24 | 06/24 | | |
NCT04120519: Thalidomide, Cyclophosphamide and Dexamethasone for Recurrent/Refractory Adult Langerhans Cell Histiocytosis |
|
|
| Recruiting | 2 | 20 | RoW | thalidomide combined with dexamethasone and cyclophosphamide | Peking Union Medical College Hospital | Langerhans Cell Histiocytosis | 12/21 | 12/21 | | |
ChiCTR2100043670: Preliminary efficacy, safety, single arm, open, non-randomized phase II clinical trial of ISABR combined with thalidomide in the treatment of advanced malignant melanoma |
|
|
| Not yet recruiting | 2 | 45 | | ISABR combined with thalidomide | Fujian Cancer Hospital; Fujian Cancer Hospital, Changzhou Pharmaceutical Factory Co., Ltd., Junshi Biotechnology Co., Ltd. | Advanced malignant melanoma | | | | |
| Not yet recruiting | 2 | 62 | NA | Thalidomide | Sixth Affiliated Hospital, Sun Yat-sen University | Chronic Radiation Proctitis | 07/22 | 12/22 | | |
NCT04382300: Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions |
|
|
| Recruiting | 2 | 39 | RoW | pyrotinib combined with thalidomide | Shanghai Chest Hospital | Non-small-cell Lung Cancer | 10/22 | 04/23 | | |
ChiCTR2100051262: Thalidomide combined with Trifluridine-Tipiracil Hydrochloride Mixture versus Trifluridine-Tipiracil Hydrochloride Mixture in the third-line or higher treatment of advanced colorectal cancer: a randomized, controlled, multicenter phase II clinical study |
|
|
| Recruiting | 2 | 120 | | Thalidomide ;None | Fujian Cancer Hospital; Fujian Cancer Hospital, Changzhou Pharmaceutical Factory Co., Ltd. | advanced colorectal cancer | | | | |
BDHCLL001, NCT03980002: A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL |
|
|
| Recruiting | 2 | 50 | RoW | FCR and Ibrutinib, BR and Ibrutinib, Ibrutinib and Thalidomide | Institute of Hematology & Blood Diseases Hospital | Chronic Lymphocytic Leukemia | 12/22 | 12/27 | | |
TACTIC, NCT05266820: Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 120 | RoW | Thalidomide, Thalidomide Tablets produced by Changzhou Pharmaceutical Factory Co. LTD, TAS-102 | Fujian Cancer Hospital | Metastatic Colorectal Cancer | 12/22 | 12/23 | | |
ChiCTR2100054610: A single-center, single-arm prospective study of thalidomide combined with hydroxyurea in the treatment of β thalassemia in children |
|
|
| Not yet recruiting | 2 | 50 | | Thalidomide + Hydroxyurea | Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, None | β-thalassemia | | | | |
ChiCTR2100052588: A clinical study of camrelizumab combined with thalidomide for the treatment of a variety of solid tumors that have previously received first-line and (or) second-line chemotherapy failure |
|
|
| Not yet recruiting | 2 | 29 | | Camrelizumab + Thalidomide | Lixin County People's Hospital; Lixin County People's Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd | Multiple solid tumors | | | | |
NCT02507336: Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165 |
|
|
| Completed | 2 | 2 | US | Thalidomide, Thalomid | University of Miami | Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma | 08/23 | 08/23 | | |
NCT02586038 / 2014-004859-31: STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS |
|
|
| Completed | 2 | 175 | Europe | MLN9708, Dexamethasone, Cyclophosphamide, Thalidomide | Mario Boccadoro | Multiple Myeloma | 10/23 | 12/23 | | |
NCT03004287: 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy |
|
|
| Active, not recruiting | 2 | 50 | US | Carfilzomib, Kyprolis, Thalidomide, Thalomid, Dexamethasone, Baycadron, Daratumumab, Darzalex, Cisplatin, Platinol, Adriamycin, Doxorubicin, Cyclophosphamide, Cytoxan, Etoposide, Eposin, Melphalan, ASCT, Lenalidomide, Revlimid, Bortezomib, Velcade | University of Arkansas, Janssen, LP | Multiple Myeloma | 10/24 | 10/25 | | |
NCT06231680: Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) |
|
|
| Recruiting | 2 | 132 | RoW | Camrelizumab, SHR-1210, Thalidomide 50mg, Thalidomide, Thalidomide 100mg, Thalidomide 200mg, Chemotherapy, Platinum-based chemotherapy | Henan Cancer Hospital, First Affiliated Hospital Xi'an Jiaotong University | Lung Cancer, Nonsmall Cell, Esophageal Carcinoma | 06/24 | 09/25 | | |
NCT03069326: A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis |
|
|
| Active, not recruiting | 2 | 30 | US | Ruxolitinib, Thalidomide | Memorial Sloan Kettering Cancer Center, Incyte Corporation, Celgene, M.D. Anderson Cancer Center | Myelofibrosis | 02/25 | 02/25 | | |
NCT06268093: The Therapeutic Effect of Thalidomide in Syringomyelia |
|
|
| Recruiting | 2 | 30 | RoW | Thalidomide | Xuanwu Hospital, Beijing | Syringomyelia, Thalidomide | 02/27 | 02/28 | | |
| Completed | 2 | 124 | Europe | Carfilzomib, Kyprolis, Thalidomide, Lenalidomide, Dexamethasone | Arbeitsgemeinschaft medikamentoese Tumortherapie, Amgen | Multiple Myeloma | 03/24 | 03/24 | | |
NCT06279351: Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 96 | NA | Thalidomide+cetuximab+FOLFOX/FOLFIRI | Xinqiao Hospital of Chongqing, Chongqing Medical University | Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer | 12/24 | 12/24 | | |
NCT04352205: Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure |
|
|
| Recruiting | 2 | 25 | US | Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Thalidomide, (+)-Thalidomide, (-)-Thalidomide, .alpha.-Phthalimidoglutarimide, 2, 6-Dioxo-3-phthalimidopiperidine, Alpha-Phthalimidoglutarimide, Contergan, Distaval, Kevadon, N-(2,6-Dioxo-3-piperidyl)phthalimide, N-Phthaloylglutamimide, N-Phthalylglutamic Acid Imide, Neurosedyn, Pantosediv, Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (+)-, Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (-)-, Sedalis, Sedoval K-17, Softenon, Synovir, Talimol, Thalomid | Emory University, Janssen Scientific Affairs, LLC, National Cancer Institute (NCI) | Plasma Cell Myeloma, Renal Failure | 04/24 | 04/24 | | |